Revenue and Profit Growth - Revenue for Q3 2022 reached ¥175,075,260.37, an increase of 116.03% compared to the same period last year[6] - Net profit attributable to shareholders was ¥60,200,473.64, reflecting a growth of 155.42% year-over-year[6] - The net profit excluding non-recurring items was ¥59,114,873.33, up 153.75% from the previous year[6] - Basic earnings per share for the quarter was ¥0.56, a 93.10% increase compared to the same period last year[6] - The company's operating revenue increased to ¥222,306,353.54, representing a growth of 89.26% compared to the same period last year, driven by a strengthened business model of "technology transformation + entrusted development + profit sharing"[14] - Total operating revenue for the third quarter of 2022 reached ¥420,743,410.29, a significant increase of 89.5% compared to ¥222,306,353.54 in the same period last year[31] - The company reported a total profit of 154,492,098.56 CNY for the quarter, compared to 70,413,983.03 CNY in the previous year, indicating an increase of about 119.8%[37] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,722,802,500.36, a decrease of 6.91% from the end of the previous year[6] - The total liabilities decreased to ¥305,608,047.34 from ¥607,099,838.11, a reduction of 49.7%[27] - Estimated liabilities rose by 46.38% to ¥125,635,824.68, as the company recognized liabilities corresponding to the progress of entrusted and self-developed projects[14] - The equity attributable to shareholders of the parent company increased to ¥2,417,361,324.83 from ¥2,317,911,097.31, an increase of 4.3%[30] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥157,648,719.74, an increase of 154.33% year-over-year[6] - The net cash flow from operating activities reached ¥157,648,719.74, a significant increase of 154.33% year-on-year, attributed to higher operating income and improved accounts receivable collection[17] - The company experienced a 240.22% increase in cash flow from investing activities, resulting in a net outflow of ¥467,493,195.28, driven by ongoing project investments[17] - Cash outflows from investing activities amounted to 471,497,885.54 CNY, compared to 228,684,414.89 CNY in the previous year, leading to a net cash flow from investing activities of -467,493,195.28 CNY[40] Expenses and Financial Performance - Research and development expenses surged by 167.37% to ¥42,489,710.84, reflecting the company's ongoing investment in innovative and generic drug development[14] - The company's income tax expense increased by 56.02% to ¥9,328,893.49, reflecting higher profits during the reporting period[17] - The financial expenses increased dramatically by 2912.60%, amounting to ¥1,177,436.68, primarily due to increased interest on raised funds[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,547, indicating a stable shareholder base[18] Inventory and Contract Assets - Inventory increased by 142.23% to ¥55,353,854.97 due to increased production activities[11] - Contract assets grew by 109.58% to ¥98,910,980.94, driven by rapid revenue growth[11] - The company reported a significant increase in prepayments, which rose by 100.91% to ¥26,603,377.79, attributed to increased clinical business activities[11] Cash and Cash Equivalents - The company reported cash outflows from financing activities amounted to 361,282,406.46 CNY, while cash inflows were recorded at 126,747,271.43 CNY, resulting in a net cash flow from financing activities of -361,282,406.46 CNY[40] - The ending cash and cash equivalents balance was 1,337,874,628.84 CNY, down from 157,569,933.40 CNY at the end of the previous year[40] - The company's cash and cash equivalents decreased to ¥1,341,573,128.84 from ¥2,013,001,510.85, a decline of 33.3%[24]
百诚医药(301096) - 2022 Q3 - 季度财报